Author:
Edwards Michael R.,Saglani Sejal,Schwarze Jurgen,Skevaki Chrysanthi,Smith Jaclyn A.,Ainsworth Ben,Almond Mark,Andreakos Evangelos,Belvisi Maria G.,Chung Kian Fan,Cookson William,Cullinan Paul,Hawrylowicz Catherine,Lommatzsch Marek,Jackson David,Lutter Rene,Marsland Benjamin,Moffatt Miriam,Thomas Mike,Virchow J. Christian,Xanthou Georgina,Edwards Jessica,Walker Samantha,Johnston Sebastian L.
Abstract
Asthma is a heterogeneous, complex disease with clinical phenotypes that incorporate persistent symptoms and acute exacerbations. It affects many millions of Europeans throughout their education and working lives and puts a heavy cost on European productivity. There is a wide spectrum of disease severity and control. Therapeutic advances have been slow despite greater understanding of basic mechanisms and the lack of satisfactory preventative and disease modifying management for asthma constitutes a significant unmet clinical need. Preventing, treating and ultimately curing asthma requires co-ordinated research and innovation across Europe. The European Asthma Research and Innovation Partnership (EARIP) is an FP7-funded programme which has taken a co-ordinated and integrated approach to analysing the future of asthma research and development. This report aims to identify the mechanistic areas in which investment is required to bring about significant improvements in asthma outcomes.
Funder
Seventh Framework Programme
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献